MetLife Investment Management LLC Invests $1.46 Million in Astrana Health, Inc. (NASDAQ:ASTH)

MetLife Investment Management LLC acquired a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 25,111 shares of the company’s stock, valued at approximately $1,455,000. MetLife Investment Management LLC owned approximately 0.05% of Astrana Health as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC purchased a new position in shares of Astrana Health during the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC acquired a new stake in Astrana Health during the third quarter valued at $35,000. KBC Group NV purchased a new position in Astrana Health in the third quarter valued at about $70,000. Quest Partners LLC acquired a new position in Astrana Health in the 3rd quarter worth about $133,000. Finally, Central Pacific Bank Trust Division purchased a new stake in shares of Astrana Health during the 3rd quarter worth about $160,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Stock Performance

NASDAQ ASTH opened at $42.90 on Friday. The company’s fifty day moving average is $51.79 and its two-hundred day moving average is $48.02. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of 33.00, a P/E/G ratio of 2.02 and a beta of 1.13. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health, Inc. has a 52-week low of $32.32 and a 52-week high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. During the same period in the previous year, the company posted $0.47 earnings per share. Equities research analysts forecast that Astrana Health, Inc. will post 1.16 EPS for the current year.

Analysts Set New Price Targets

ASTH has been the topic of a number of research reports. Robert W. Baird increased their price objective on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. KeyCorp assumed coverage on shares of Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. BTIG Research upped their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen assumed coverage on Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 target price on the stock. Finally, Truist Financial upped their price target on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Astrana Health currently has a consensus rating of “Buy” and a consensus price target of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.